<DOC>
	<DOCNO>NCT01358877</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , two-arm study ass safety efficacy pertuzumab addition chemotherapy plus trastuzumab adjuvant therapy participant operable HER2-positive primary breast cancer . After surgery , participant randomize receive either pertuzumab placebo intravenously ( IV ) every 3 week ( q3w ) one year , along 6-8 cycle chemotherapy 1 year trastuzumab IV every 3 week . This study carry collaboration Breast International Group ( BIG ) .</brief_summary>
	<brief_title>A Study Pertuzumab Addition Chemotherapy Trastuzumab Adjuvant Therapy Participants With Human Epidermal Growth Receptor 2 ( HER2 ) -Positive Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Nonmetastatic operable primary invasive HER2positive carcinoma breast histologically confirm , adequately excised Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; /= ) 1 The interval definitive surgery breast cancer first dose chemotherapy must 8 week ( 56 day ) . The first cycle chemotherapy must administer within 7 day randomization Day 56 , whichever occur first Known hormone receptor status ( estrogen receptor progesterone receptor ) Baseline LVEF great equal ( &gt; /= ) 55 percent ( % ) measure echocardiogram ( ECHO ) MultipleGated Acquisition ( MUGA ) Scan Confirmed HER2 positive status Women childbearing potential male participant partner childbearing potential must agree use effective contraception ( define protocol ) participant and/or partner duration study treatment least 7 month last dose study drug History prior ( ipsi and/or contralateral ) invasive breast cancer History nonbreast malignancy within 5 year prior study entry , except carcinoma situ cervix , carcinoma situ colon , melanoma situ , basal cell squamous cell carcinoma skin Any `` clinical '' T4 tumor define Primary tumor/regional lymph nodes/distant metastasis ( TNM ) , include inflammatory breast cancer Any previous systemic chemotherapy cancer radiotherapy cancer Prior use antiHER2 therapy reason prior biologic immunotherapy cancer Concurrent anticancer treatment another investigational trial Serious cardiac cardiovascular disease condition Other concurrent serious disease may interfere plan treatment include severe pulmonary conditions/illness Abnormal laboratory test immediately prior randomization Pregnant lactate woman Sensitivity study medication ingredient excipients medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>